Relationship between tumour necrosis factor-alpha (TNFα) production and a specific multiple sclerosis (MS) associated TNF gene haplotype

Abstract

Objective: To determine if monocyte TNFa production from patients homozygous for a specific MS associated TNF gene haplotype is different from that produced in patients either heterozygous for, or without this haplotype. Background: The balance between pro- and anti-inflammatory cytokines is important in the clinical outcome of inflammatory reactions. Levels of TNFa, a pro-inflammatory cytokine, is raised in MS as well as being found in acute and chronic MS lesions. A previous population based study in Northern Ireland with polymorphisms spanning the TNF gene region identified a conserved MS associated haplotype in relation to three markers (130: 118: 127 TNF d: a: b) for which 19 MS patients were homozygous. Methods: Venous blood collected in EDTA to give a concentration of 10⁷ ³ M was drawn from 16 patients with the conserved MS associated haplotype, 19 patients heterozygous for the haplotype and 17 patients without the haplotype. Mononuclear cells were separated and cultured by standard techniques and levels of TNFa and of TNF binding proteins I and II were determined by commercial enzyme-linked immunosorbent assays. Results: There were no significant differences in TNFa production in the 3 h (P=0.28) or 24 h cultures (P=0.18) or following stimulation with interferon-g (P=0.17) between the group positive for the conserved haplotype and the group negative for this haplotype. There was also no significant difference when compared to the heterozygote group. No association was found between the MS associated haplotype and levels of either TNF binding protein. A greater proportion of patients with the conserved haplotype had a benign clinical course (P=0.06). Conclusion: We conclude that whilst a trend exists, we have found no significant association between peripheral TNFa production and a specific MS associated TNF haplotype in this population. Paradoxically this haplotype may also predict a more favourable clinical course.

Keywords

tumour necrosis factor-alpha tumour necrosis factor receptors monocytes association studies cytokines multiple sclerosis

Get full access to this article

View all access options for this article.

References

Armstrong MA , Haire M. (1986) Ecto-5' nucleotidase activity in B and T lymphocytes and monocytes of patients with multiple sclerosis. Ann Neurol 19: 94-96.

Armstrong MA , Crockard AD , Hawkins SA , McNeill TA. (1987) Multiple sclerosis and gamma interferon. Lancet 1: 1369-1370.

Armstrong MA et al. (1988) Reduction of monocyte 5' nucleotidase activity by g-interferon in multiple sclerosis and autoimmune diseases. Ann Neurol 24: 12-16.

Armstrong MA , Fleming E , Clarke G , Hawkins SA. (1996) Interleukin-10 and g-interferon-interactions in multiple sclerosis. Eur Cytokine Network 7: 456-456.

Mossman TR. (1994) Interleukin-10. In: Thompsom AW (ed). The Cytokine Handbook, 2nd ed. Academic Press pp 233-237.

Hofman FM , Hinton DR , Johnson K , Merrill JE. (1989) Tumour necrosis factor identified in multiple sclerosis brain. J Exp Med 170: 607-612.

Selmaj KW , Raine CS , Cannella B , Brosnan CF. (1991) Identification of lymphotoxin and tumour necrosis factor in multiple sclerosis lesions. J Clin Invest 87: 949-954.

Glabinski A , Mirecka M , Pokoca L. (1995) Tumour necrosis factor alpha but not lymphotoxin is over-produced by blood mononuclear cells in multiple sclerosis. Acta Neurol Scand 91: 276-279.

Selmaj KW , Raine CS. (1988) Tumour necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23: 339-346.

10.

Selmaj KW et al. (1990) Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumour necrosis factor. J Immunol 144: 129-135.

11.

Aggarwal BB , Eessalu TE , Haas PE. (1985) Characterisation of receptors for human tumour necrosis factor and their regulation by g-interferon. Nature 318: 665-667.

12.

Baglioni C , McCandless S , Tavernier J , Fiers W. (1985) Binding of human tumour necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition. J Biol Chem 260: 13395-13397.

13.

Hohmann HP , Remy R , Brockhaus M , van Loon APGM. (1989) Two different cell types have different major receptors for human tumour necrosis factor (TNFa). J Biol Chem 264: 14927-14934.

14.

Brockhaus M et al. (1990) Identification of two types of tumour necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 87: 3127-3131.

15.

Mohler KM et al. (1993) Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxaemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151: 1548-1561.

16.

Rieckmann P et al. (1994) Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 44: 2367-2372.

17.

Matsuda M , Tsukada N , Miyagi K , Yanagisawa N. (1994) Increased levels of soluble tumour necrosis factor receptor in patients with multiple sclerosis and HTLV- 1-associated myelopathy. J Neuroimmunol 52: 33-40.

18.

Selmaj K , Papierz W , Glabinski A , Kohno T. (1995) Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumour necrosis factor receptor I. J Neuroimmunol 56: 135-141.

19.

Udalova IA et al. (1993) Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics 16: 180-186.

20.

Kirk CW et al. (1997) Tumour necrosis factor micro-satellites show association with multiple sclerosis. J Neurol Sci 147: 21-25.

21.

Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231.

22.

Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.

23.

Weinshenker BG et al. (1997) Genetic variation in the tumour necrosis factor alpha gene and the outcome of multiple sclerosis. Neurology 49: 378-385.